CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the company’s Investors "Events & Presentations" page. A replay will be archived for 14 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CRSP
On the day this news was published, CRSP gained 1.12%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with names like MRUS and LEGN down while PTCT, TGTX, and RNA are up or modestly positive. With only one peer in the momentum scanner and a small -0.73% move in CRSP, trading appears more stock-specific than part of a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Convertible notes pricing | Negative | -5.4% | Upsized $550M 2031 convertible notes pricing with added $50M option. |
| Mar 10 | Convertible notes offering | Negative | -10.2% | Announcement of proposed $350M 2031 convertible senior notes financing. |
| Feb 12 | Earnings and pipeline | Positive | +8.5% | Q4/FY 2025 results with CASGEVY revenue and broad pipeline progress. |
| Jan 12 | Strategic priorities update | Positive | +2.7% | Outlined 2026 milestones, cash of ~$2B, and CASGEVY >$100M revenue. |
| Jan 05 | Conference appearance | Neutral | +2.6% | J.P. Morgan Healthcare Conference presentation and webcast details. |
Stock has tended to sell off on financing announcements while responding positively to business updates and strategic news.
Over the last few months, CRISPR Therapeutics has balanced strategic progress with financing activity. A January strategic update and J.P. Morgan conference appearance coincided with modest gains, while February earnings and a business update saw a stronger +8.46% move. In March, proposed and upsized convertible note offerings triggered -10.17% and -5.44% reactions. Today’s conference appearance resembles prior non-financial news items that mainly reinforced visibility rather than changing fundamentals.
Market Pulse Summary
This announcement adds another investor-relations touchpoint, with management presenting at the Needham conference on April 13 and offering a webcast and 14-day replay. Recent history shows the stock reacting more strongly to financing steps and earnings or pipeline milestones than to conference appearances. Given prior convertible note offerings and the stock trading below its $56.22 200-day MA, investors may focus on any qualitative commentary that updates those broader themes.
AI-generated analysis. Not financial advice.
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, Apr 13 at 2:15 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
